Posted in Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials April 16, 2026 Pharmaceutical Technology The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been addressed by the ACHIEVE-4 trial. Clinical DataMetabolic & GLP-1Read full story